SWOG earlier this week started to accrue patients to Lung-MAP, a clinical trial for second-line treatment of non-small cell lung cancer.
Caris Life Sciences
It's possible that molecular testing is doing a lot of good, pinpointing cancer therapies that are most likely (or least likely) to work.
Tumor profiling information Caris Life Sciences provides in its reports isn't backed by sufficient evidence to justify some clinical decisions, said Daniel Hayes, a breast cancer expert at the University of Michigan.
